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1. Introduction  
The carcinogenesis and progression of hepatocellular carcinoma (HCC) are complicated 
processes which evolve through distinct stages associated with cumulative genomic 
alterations, which result in deregulation of proliferation, metastasis and recurrence, leading 
to poor prognosis. Despite the fact many new therapeutic and diagnostic strategies for 
cancer have been developed in recent years, the cure rate for HCC has not satisfactorily 
improved and biomarkers currently used for HCC diagnosis are not satisfactory in either 
their specificity or sensitivity.  
More than one thousand cancer-associated genes and proteins have been identified, but the 
pathogenesis of hepatocellular carcinoma is still incompletely understood. Identifying the as 
yet unknown pivotal genes and proteins will be critical for early diagnosis, effective 
monitoring and novel therapies for this highly aggressive cancer. In previous work we 
cloned and identified a novel HCC-associated gene (lysosomal protein transmembrane 4 
beta, LAPTM4B). Its complementary mRNA is highly expressed in the vast majority of HCC 
samples as compared with paired noncancerous liver from the same patient (PNL), fetal 
liver, and normal liver (Shao et al., 2003). Over our past decade studies have demonstrated 
that the LAPTM4B gene and the LAPTM4B-35 protein which it encodes would be pivotal 
diagnostic biomarkers and therapeutic targets for hepatocellular carcinoma. 
2. LAPTM4B: A novel gene associated with hepatocellular carcinoma 
2.1 Identification and cloning of the LAPTM4B gene 
To search for genes involved in deregulation of proliferation and aberrant differentiation for 
hepatocellular carcinoma, fluorescent-differential display was performed using human liver 
tissues, including adult liver, fetal liver, HCC and its paired samples of noncancerous liver 
from the same patient (paired noncancerous liver). A cDNA fragment, which was not a part 
of any known gene, was found from 110 differential display fragments obtained. This cDNA 
fragment was highly expressed in HCC, significantly expressed in fetal liver and the paired 
noncancerous liver, but showed very low expression in normal adult liver (JJ. Liu et al., 
2000). Cloning the full length cDNA (NM_018407, ID=55353, Figure 1) harboring this 
fragment was performed by Expressed Sequence Tag (EST) splicing, 5’ rapid amplification 
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of cDNA ends (FACE) and reverse transcription-polymerase chain reaction (RT–PCR). 
Based on the lysosome-targeting signal (YXXΦ) found on the encoded protein this gene was 
originally designated by the HUGO Gene Nomenclature Committee as “lysosomal-
associated protein transmembrane 4 beta” (LAPTM4B) and this designation was then 
revised as “lysosomal protein transmembrane 4 beta” (LAPTM4B). Importantly, it should be 
emphasized that reverse-transcription from total RNA to synthesize this cDNA must be 
conducted at 65o C using the ThermoScript RT-PCR Systems (Gibco-BRL) as there is very 
high content of GC at the 5’ terminus (Shao et al., 2003), otherwise full length LAPTM4B 
cDNA cannot be obtained. BLAST program analysis shows that the LAPTM4B gene maps to 
chromosome 8q22.1, spanning at least 50 kb composed of seven exons separated by six 
introns, and contains a 951bp open reading frame (ORF). LAPTM4B mRNA is 
approximately 2.16 kb in length and which is consistent with the size of the mRNA observed 
in Northern blots. Two polyadenylation signal sites, AATAAA and AATTAAA are present 
at the 3’ UTR (Figure 1). The former polyadenylation site (AATAAA) may result in another 
1.42 kb mRNA variant (Shao et al., 2003). 
 
Fig. 1. The nucleotide sequence of LAPTM4B cDNA and the deduced amino-acid sequence. 
The sequence numbers of the first nucleotide (left) and the final amino acid (right) in each 
row is indicated, respectively. Exon divisions are indicated by   . The polyadenylation 
consensus sequences (AATAAA, AATTAAA) are underlined. Transmembrane regions are 
boxed. The putative N-glycosylation site is marked with a ring of hexagon; potential 
phosphorylation sites are circled, with the corresponding kinases indicated in italic 
characters. Stop codon or inframe stop codons are indicated as # or *. The PPRP and YXXΦ 
motifs are boxed with red line of dashes. (Shao et al., 2003)  
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2.2 Bioinformatics analysis of LAPTM4B proteins  
Bioinformatics shows that the full-length cDNA sequence of LAPTM4B contains two 
translational initiation codons (ATG) separated by an interval of 273 bp and therefore, 
encodes two protein isoforms with apparent molecular weights of 35 kDa containing 317 
amino acid residues and 24 kDa containing 226 amino acid residues, which are designated 
LAPTM4B-35 and LAPTM4B-24. LAPTM4B-35 has a pI at 9.07 due to its high content of 
arginine residues, while LAPTM4B-24 has a pI at 4.65 resulting from a high content of acidic 
amino acid residues. Computer analysis shows that LAPTM4B is an integral membrane 
glycoprotein (Figure 2), with four transmembrane regions, two extracellular domains (EC1 
and EC2), one small intracellular loop, together with one N-terminal and one C-terminal tail 
which reside in the cytoplasm. One potential N-glycosylation site is present in the EC1 
domain and several O-glycosylation sites may also be present. LAPTM4B-35 contains six 
putative intracytoplasmic phosphorylation sites, including one tyrosine phosphorylation 
site at Try 285, and four N-myristylation sites. Compared to LAPTM4B-24, LAPTM4B-35 has 
an extra 91 amino acid sequence in its N-terminus that harbors a proline-rich domain, which 
serves as the binding site of the SH3 domain in some signaling molecules. A conserved 
YXXф (Y represents tyrosine, ф represents a large hydrophobic amino acid, X represents 
any amino acid) motif in the C-terminal tail is believed to function as a signal for targeting 
to lysosomal membranes and sorting.  
 
Fig. 2. Topology of LAPTM4B-35 (left) and LAPTM4B-24 (right) proteins   
2.3 Expression of LAPTM4B mRNA and protein in normal tissues and cancer tissues 
Expression of LAPTM4B mRNA has been evaluated by Northern blot and RT-PCR, and 
found to be widely expressed in human tissues. Its expression is highest in the heart, 
skeletal muscle and uterus, and more high in testis and ovary. Expression is moderate in the 
kidney and pancreas, and low in the liver, spleen and thymus, but is lowest in the lung and 
peripheral leukocytes (Figure 3a) (Shao et al., 2003; Kasper et al., 2005). High expression is 
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also seen in fetal heart, kidney and spleen (Figure 3b). Expression of LAPTM4B mRNA in 
HCC has been confirmed by Northern blot (Figure 4a), RT-PCR and hybridization in situ 
(Figure 4b). The frequency of LAPTM4B mRNA over-expression as demonstrated by 
Northern blot is as high as 87.3% (Shao et al., 2003); Expression of LAPTM4B-35 and 
LAPTM4B-24 proteins in tissues have been demonstrated by Western blot and 
immunohistochemistry (IHC). As shown by Western blot (Figure 5a), LAPTM4B-35 is 
much more abundant than LAPTM4B-24 in the liver and HCC. In other words, over-
expression of LAPTM4B-35 but not LAPTM4B-24 presents in HCC, and the ratio of 
LAPTM4B-35 to LAPTM4B-24 is thus markedly increased in HCC (X. Liu et al., 2004). The 
frequency of LAPTM4B-35 up-regulation is also extremely high (Figure 5b), and it has 
been shown that T/N>1.5 [T=tumor)/N =paired non-cancerous liver] is found in 87.7% 
(57/65) of HCC, T/N>2 in 76.9% (50/65) of HCC and T/N>4 in 61.5% (40/65) of HCC 
(Yang et al., 2010a). More importantly, the levels of LAPTM4B-35 in HCC tissues are 
significantly associated with pathological grades, TNM staging, portal vein invasion and 
recurrence, but not with age, gender, viral status, tumor size and serum AFP levels (Table 
1, Yang et al., 2010a). Moreover, LAPTM4B mRNA and LAPTM4B-35 over-expression also 
occurs in a wide range of hepatocellular carcinoma- and other cancer-derived cell lines 
(Shao et al., 2003; XR. Liu et al., 2004). 
 
 
 
 
 
Fig. 3. LAPTM4B mRNA expression in normal human tissues analyzed by Northern blot 
with a LAPTM4B prob (corresponding to nt 1876-2171 on NM_018407). 
(a) Expression of LAPTM4B mRNA in adult human tissues (b) Expression of LAPTM4B 
mRNA in fetal human tissues (Shao et al., 2003) 
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Fig. 4. LAPTM4B mRNA expression in hepatocellular carcinomas (HCCs) tissues and HCC-
derived cell lines analyzed by Northern blot with a LAPTM4B prob (corresponding to nt 
1876-2171 on NM_018407). (a) Northern blot analysis of LAPTM4B. Upper panel: HCC 
tissues (T), paired noncancerous liver tissues (N), fetal and adult normal liver tissues (F- & 
A-liv); Lower panel: The human liver- and HCC-derived cell lines, and mouse HCC-derived 
cell lines. (b) Hybridization in situ was performed on tissue sections. LAPTM4B mRNA 
expressions in HCC tissue (i, ii), paired noncancerous tissue (iii), and BEL7402 cells (iv). 
Positive LAPTM4B mRNA expression was preferentially in hepatic cancerous cells as 
indicated by blue-purple staining. Original magnification, 40 (i, iii) or 100 (ii, iv). (c) Positive 
correlation between LAPTM4B mRNA levels and tumor grades. Each spot in the figure 
represents the ratio of tumor vs. paired noncancerous liver tissue (T/N) of the LAPTM4B 
mRNA expression evaluated by Northern blot. These spots derived from 55 HCC patients. 
(Shao et al., 2003) 
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Fig. 5. Expression of LAPTM4B-35 and LAPTM4B-24 protein identified by Western blot in 
HCCs and paired noncancerous liver tissues (PNL) from the same one patient. 
(a) Expression of LAPTM4B-35 and LAPTM4B-24 was evaluated by Western blot with an 
anti-LAPTM4B-EC2 pAb, which reacts with both LAPTM4B-35 and LAPTM4B-24, and anti-
LAPTM4B-N-pAb, which reacts with merely LAPTM4B-35. It is shown that LAPTM4B-35 is 
much more abundant than LAPTM4B-24 in the normal liver (NL) and HCC. (b) Expression 
of LAPTM4B-35 detected with Anti-LAPTM4B-N-10 pAb. The upper panel shows the 
expression of LAPTM4B-35 in HCC (T) and paired noncancerous liver tissues (N) tissues. 
Densitometry was normalized with -actin. The middle panel shows the levels of 
LAPTM4B-35 in HCC tissues derived from 65 patients. The lower panel shows the levels of 
LAPTM4B-35 in the paired noncancerous liver tissues derived from the same 65 patients. 
(Yang et al., 2010a). 
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Variables Patients (n) 
LAPTM4B-35 expression 
Pa 
Low Middle High 
All cases 65 15 30 20  
Gender     0.434 
Male 53 11 24 18  
Female 12 4 6 2  
Age (years)     0.544 
＜60 42 8 21 13  
≥60 23 7 9 7  
Cirrhosis     0.013 
Yes 44 6 25 13  
No 21 9 5 7  
Viral status     0.766 
Hepatitis virus B 46 9 23 14  
Hepatitis virus C 12 4 5 3  
Both hepatitis virus B and C 2 0 1 1  
Non-B, Non-C 5 2 1 2  
Tumor size     0.421 
＜5 cm 34 10 15 9  
≥5 cm 31 5 15 11  
Invasive tumor     <0.001 
Yes 17 0 4 13  
No 48 15 26 7  
Histopathological 
differentiation 
    
<0.01b 
 
Well Differentiation (WD) 18 6 8 4  
Middle Differentiation (MD) 24 7 11 6  
Poor Differentiation (PD) 23 2* 11 10*  
Serum AFP level     0.517 
＜25 ng/ml 32 6 17 9  
≥25 ng/ml 33 9 13 11  
TNM stage     <0.001 
I 16 11 3 2  
II 21 2 14 5  
III—IV 28 2 13 13  
a: Chi-square test;   
b: p<0.01: Low expression vs. High expression for PD group.  
Table 1. Relationship between LAPTM4B-35 expression and Clinical-pathological features of 
HCC (Yang et al., 2010a) 
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In addition, over-expressions of LAPTM4B mRNA and LAPTM4B-35 protein have also been 
found in other solid cancers. Kasper et al. (2005) reported that LAPTM4B mRNA tested by 
Northern Blot is over-expressed in 88% of lung cancer, 50.9% of breast cancers, 67% of colon 
cancers, 68% of uterus cancers, and 37% of gastric cancers. Peng et al. (2005) reported that 
LAPTM4B-35 protein as evaluated by immuno-histochemistry (IHC) is highly expressed in 
lung cancer, stomach cancer, colon cancer and breast cancer. Subsequently, the frequency of 
over-expression of LAPTM4B-35 in more cases of various cancers was determined, and was 
found in 76 ％ of gallbladder cancers (Zhou et al., 2007), 72 ％ of cholangiocarcinomas (Zhou 
et al.,. 2008), 63.5% of ovarian cancers (Yang et al., 2008; Yin et al., 2010), 72.57% of cervical 
cancers (Meng et al., 2010a) and 70.91% of endometrial cancers (Meng, et al., 2010b). 
However, the mechanism for over-expression of LAPTM4B in HCC and other cancers has 
not as yet been completely elucidated. Mutation and demethylation of LAPTM4B gene has 
not been found. Nevertheless, it has been reported in a large number of articles that the 
chromosome 8q region harboring LAPTM4B gene is amplified as shown by fluorescence in 
situ hybridization (FISH) or gained as shown by comparative genomic hybridization (CGH) 
in both hepatoblastoma and hepatocellular carcinoma (Buendia et al., 2002; Longerichet al., 
2011; Marchio et al., 1997). More precisely, it has been recently reported that chromosome 8q 
22 where the LAPTM4B gene localizes is amplified or gained in breast cancer (Hu et al., 
2009; Y. Li. et al., 2010). Therefore, gene amplification may be the cytogenetic basis of 
LAPTM4B over-expression. However, the genomic DNA copy number alterations of most 
genes in general do not appear to parallel corresponding transcriptional expression (Huang 
et al., 2006). It is reasonable to propose that transcriptional up-regulation by transcription 
factors and/or microRNAs may also contribute to LAPTM4B-35 over-expression in cancers. 
A more in-depth analysis will be required to clarify these points. 
2.4 LAPTM4B alleles and their significance in susceptibility for hepatocarcinogenesis 
Two alleles of the LAPTM4B gene have been identified in our laboratory and designated 
LAPTM4B *1 and *2. Allele *2 differs from allele *1 in that it contains an extra tandemly 
arranged 19-bp (gcttggagctccagcagct) sequence at the 5’UTR in the first exon. A PCR-based 
method was established for genotyping of this gene using the primers 5’ 
GCCGACTAGGGGACTGGCGGA 3’ and 5’ CGAGAGCTCCGAGCTTCTGCC 3’ to amplify 
the partial sequence of exon 1, and using genomic DNA as the template. To investigate the 
relationship between the allelic variants of LAPTM4B and the susceptibility to HCC or 
esophageal squamous cell carcinoma (ESC), patients with HCC or ESC, and two control 
groups of normal individuals from the corresponding regions were analyzed. Significant 
differences in the frequency of genotype LAPTM4B*2/2 were found in patients with HCC 
(17.4%) as compared with the controls (10.2%) (p<0.05), indicating that individuals with the 
*2/*2 genotype are more susceptible to HCC than *1/*1 and *1/*2 individuals (Table 2). 
However, no difference was observed in the frequencies of LAPTM4B genotypes in patients 
with ESC as compared with corresponding controls. These results suggest that allele *2 may 
be associated specifically with susceptibility to HCC. In conclusion, our data suggest that 
LAPTM4B*2/*2 is associated with susceptibility to HCC and the LAPTM4B genotype 
provides a new means for screening for people who are susceptible to primary 
hepatocellular carcinoma. This may be of importance for the assessment and prevention of 
developing hepatocellular carcinoma in high risk populations, in particular for the patients 
with liver cirrhosis of small liver nodule from HBV and HCV chronic infection (Shao et al., 
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unpublished data). In addition, allele *2 has been found to be associated with increased risk of 
lung cancer (Deng et al., 2005), stomach cancer (Liu et al., 2007), cervical carcinoma (Meng et 
al., 2011) and colon cancer but not of rectal cancer (Cheng et al., 2008). These results indicate 
that LAPTM4B *2 is also a potential risk factor for the development of some solid cancers. 
 
 
N (%) 
 
P value 
Controls 
(n=206) 
HCC 
(n=184) 
LAPTM4B genotype 
*1/1 97 (47.1) 77(41.8)  
*1/2 88 (42.7) 75 (40.8)  
*2/2 21 (10.2) 32 (17.4) 0.038a 
Allele frequency 
*1 0.68 0.62  
*2 0.32 0.38  
a : when compared with the combined frequency of 1/1 and 1/2;  
OR: 1.855, 95%CI: 1.027 – 3.348 
Table 2. Distribution of LAPTM4B genotypes in HCC and Controls 
2.5 LAPTM family  
In addition to LAPTM4B, LAPTM4A (Hogue et al., 1996) and LAPTM5 (Adra et al., 1996) 
are also members of lysosome-associated protein transmembrane (LAPTM) family. 
LAPTM4A (27kDa) shows a 46% homology with LAPTM4B in amino acid sequences. In 
comparison with LAPTM4B-35 containing 317 amino acid residues, LAPTM4A containing 
233 amino acid residues and LAPTM5 containing 262 amino acid residues both are of the N-
terminus-truncated molecules of LAPTM family. The three members in the LAPTM family 
all localize at late endosomes and lysosomes, and play an important role in lysosomal 
function, including transporting structurally unrelated amphiphilic molecules between 
cytosol and lysosomes, and are involved in autophagocytosis. Moreover, LAPTM4B, 
LAPTM4A and LAPTM5 interact and co-localize with mucolipin 1, which is a lysosomal ion 
channel that belongs to the transient receptor potential (TRP) superfamily and their loss-of-
function mutations result in mucolipidosis type IV (MLIV), a lysosomal storage disorder 
characterized by severe mental and psychomotor retardation (Vergarajauregui et al., 2011). 
LAPTM4A is involved in the subcellular compartmentalization of diverse hydrophobic 
small molecules and contributes to the inherent drug sensitivity or resistance of the 
mammalian cell (Hogue et al., 1999). The LAPTM5 gene maps to chromosome 1p34 and is 
expressed mainly in hematopoietic cells and immune cells (Adra et al., 1996). LAPTM5 
protein physically interacts with the B cell receptor (BCR) complex and promotes its 
degradation in the lysosomal compartment in mouse B cells, and thus negatively regulates 
cell surface BCR levels and B cell activation (Ouchida, 2010). The expression of LAPTM5 
gene is usually down-regulated through DNA methylation in a neuroblastoma cell-specific 
manner, while over-expression of this gene may induce spontaneous regression of 
neuroblastomas. It is believed that caspase-independent lysosomal cell death due to 
lysosomal destabilization resulted from LAPTM5 up-regulation is closely associated with 
the spontaneous regression (Inoue et al., 2009).  
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Notably, LAPTM family shows similarity in some functional characteristics to “tetraspanin” 
family, but difference in the structural characteristics, including lacking some conserved 
amino acid residues and having a smaller EC2 domain. (Maecker et al., 1997; Martin, 2005).  
Evolutionarily, LAPTM is an ancient and conserved gene family in mammalian species as 
well as in lower eukaryotic organisms, including zebrafish (Danio rerio) and Drosophila. 
The phylogenic tree shown in Figure 6 is constructed according to multiple sequence 
alignment results. It shows that LAPTM4B and the other two genes in the LAPTM family, 
LAPTM4A and LAPTM5, are distributed in clusters. Human LAPTM4B shows the closest 
similarity to Bos Taurus, and also shows some similarity to its zebrafish homolog. In 
addition, LAPTM4B is more related to LAPTM4A than LAPTM5. 
  
Fig. 6. The evolutionary lineage tree for LAPTM family (This figure was prepared by 
Shuang Shi) 
3. Functions of LAPTM4B-encoding proteins and the mechanisms thereof 
Functional studies of LAPTM4B-encoding proteins and the mechanisms thereof have been 
performed via transgenic and gene knockdown techniques. LAPTM4B cDNA is introduced 
into plasmids with or without a FLAG tag, or into an E1/E3-deleted replication-deficient 
adenovirus type 5 (Ad5) vector. The LAPTM4B-35 expressing plasmids and cells are all 
designated in our publications as “AF” if they have a FLAG tag or as “AE” if they do not 
have a FLAG tag. Similarly, LAPTM4B-24 expressing plasmids and cells are designated as 
“BF” or “BE”. LAPTM4B-35 knockdown is performed by transfection of shRNA-expressing 
plasmids (Yang et al., 2010c). These functional studies of LAPTM4B-35 and LAPTM4B-24 
have determined that these two isoforms of LAPTM4B proteins have antagonistic functions, 
namely up-regulation of LAPTM4B-35 and LAPTM4B-24 respectively promotes and 
suppresses hepatocarcinogenesis and metastasis.  
3.1 Over-expression of LAPTM4B-35 promotes carcinogenesis and metastasis of 
hepatocellular carcinoma 
The effect of LAPTM4B over-expression on carcinogenesis was first explored using mouse 
NIH3T3 fibroblast cell line (He et al., 2003). Two cell lines stably over-expressing both 
LAPTM4B mRNA and LAPTM4B-35 were obtained from transfection of LAPTM4B cDNA 
integrated in plasmids. The LAPTM4B-35 over-expressing NIH3T3-AE cells generated a 
palpable mass by day 7 in all sites of inoculation in NIH3T3 mice, while in the control 
groups inoculated with NIH3T3-Mock cells or NIH3T3 parent cells, no tumor appeared 
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within an 80 day period following inoculation. Half of the tumor masses generated from 
LAPTM4B-overexpressing NIH3T3-AE cells showed growth and were histochemically 
identified as malignant fibrosarcoma; the other half of these masses regressed and were 
finally identified as liquid lymphoid tissue. Further, the L02 cell line which originated from 
normal human liver was then used to generate a LAPTM4B-35 over-expressing cell model 
by infection with replication deficient adenovirus Ad-AE containing LAPTM4B-35 full 
length cDNA (Lily et al., 2011). Inoculation of LAPTM4B-35 over-expressing L02-AE cells 
can result in rapidly growing carcinoma xenografts in 100% (6/6) of inoculated sites in the 
left axilla of nude mice (Figure 7a and 7b) and shorten their live span (Figure 7d) , as  
 
Fig. 7. Upregulation of LAPTM4B-35 promotes tumorigenesis in nude mice. (a) Xenograft 
tumors formed from L02-Ad-AE cells, in which LAPTM4B-35 is overexpressing, and tumors 
formed from L02-Ad-Null cells which are indicated by white arrows. (b) Tumor growth 
curves from L02-Ad-AE cells and L02-Ad-Null cells. (c) Top panel: H&E staining of tumor 
formed from L02-Ad-Null cells (left) and L02-Ad-AE cells (right). Black arrows indicate the 
cancer cells in blood vessel. Bottom panel: immunohistochemical evaluation of LAPTM4B-
35 expression in xenografts. Tumors derived from L02-Ad-AE cells showed high expression 
of LAPTM4B-35 (right), but tumors derived from L02-Ad-Null cells showed very low 
expression of LAPTM4B-35 (left). An anti-LAPTM4B-N10 pAb, which specifically reacts 
with LAPTM4B-35, was used for IHC (original magnification 200X). (d) Kaplan–Meier 
survival curves plotted with SPSS 16.0 (n=6). LAPTM4B-35 up-regulation shortened the live 
span of mice challenged with L02-Ad-AE cells, as compared to the control group infected by 
Ad-null, the empty Ad vectors. P=0.049 L02-Ad-AE versus L02-Ad-Null. (Lily et al., 2011).  
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Fig. 8. LAPTM4B-35 promotes tumor growth and metastasis in nude mice. (a) 
Representative xenograft tumors formed from HepG2-AE cells over-expressing LAPTM4B-
35 and HepG2-shRNA cells with LAPTM4B-35 knockdown, and corresponding controls 
(HepG2-mock1 cells and HepG2-mock2 cells), (b) Tumor growth curves from HepG2-AE 
and HepG2-mock1 control cells (left), and from HepG2-shRNA and HepG2-mock2 control 
cells (right). (c) Average tumor weight in nude mice sacrificed 7 weeks after inoculation 
with HepG2-AE and HepG2-mock1 control cells (left), and with HepG2-shRNA and HepG2-
mock2 control cells (right). n = 6. (P < 0.001: HepG2-AE vs. HepG2-mock1 and HepG2-
shRNA vs. HepG2-mock2). For all data the mean and standard deviation represent the 
average of three independent experiments. (d) LAPTM4B-35 promotes tumor metastasis in 
nude mice: Macroscopic photos and microscopic photos shown by H&E staining of tumor 
metastases in lymph nodes and lungs of mice subcutaneously inoculated with BEL7402-AE 
cells (upper panels), BEL7402–shRNA cells (lower panels) or corresponding control cells. 
(Yang et al., 2010c) 
compared to the control group infected by Ad-null, in which very small tumors were 
formed in the right axilla of nude mice (Figure 7a as indicated by the white arrows). The 
xenografts, which were generated from L02-AE cells, expressed high levels of LAPTM4B-35 
as shown by immunohistochemistry (Figure 7c bottom right panel), and these tumors were 
very well vascularized and tumor blood vessels showed invasion of cancer cells by H&E 
staining (Figure 7c top right panel). These findings demonstrated that LAPTM4b-35 over-
expressing liver cells have potential for hepatocarcinogenesis and metastasis. In addition, 
the HepG2 cell line which originated from human hepatoblastoma and the BEL7402 cell line 
which originated from human hepatocellular carcinoma were used for generating up-
regulated and down-regulated cell models to study the effects of LAPTM4B-35 on tumor 
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growth and metastasis (Yang et al., 2010c). The xenografts in nude mice originating from 
HepG2-AE and BEL7402-AE cells, in which LAPTM4B-35 has been up-regulated, grow 
significantly faster  (Figure 8a, 8b and 8c left pannel) and with greater numbers of more 
widespread metastases in the lymph nodes and lungs than the control group transfected by 
Mock (empty) plasmids (Figure 8d upper panels). Conversely, the xenografts in nude mice 
originating from HepG2-RNAi and BEL7402-RNAi cells, in which endogenous LAPTM4B-
35 has been knocked down, grow significantly slower (Figure 8a, 8b and 8c right panel). At 
the same time, metastases in the lymph nodes and lungs in the HepG2-shRNA and 
BEL7402-shRNA groups were also fewer and smaller than in the corresponding control 
groups (Figure 8d lower panels). Overall these experiments demonstrate that up-regulation 
of LAPTM4B-35 promotes HCC growth and metastasis, while down-regulation has an 
inhibitory effect. 
3.2 Over-expression of LAPTM4B-35 induces deregulation of proliferation 
Promotion and inhibition of proliferation by LAPTM4B-35 up-regulation and down-
regulation respectively has been demonstrated conclusively using L02-AE, BEL7402-AE, 
HepG2-AE and HLE-AE cell lines, together with BEL7402-RNAi and GepG2-RNAi cells (L. 
Li et al,. 2011; XR. Liu et al., 2009; H.Yang et al., 2010c). Except the L02 cell line was 
originally derived from normal liver, the BEL7402, HepG2 and HLE cell lines were all 
originally derived from human HCCs. It is noteworthy that up-regulation of LAPTM4B-35 
not only accelerates cell proliferation (Figure 9a, 9b and 9c), but also induces deregulation 
of proliferation, which is a characteristically neoplastic phenotype. HLE-AE, BEL7402-AE 
and HepG2-AE cells in which LAPTM4B-35 has been up-regulated, generate colonies 
which are significantly larger and greater in number; whereas HepG2-RNAi and 
BEL7402-RNAi cells in which the endogenous LAPTM4B-35 has been down-regulated 
produce markedly smaller and fewer colonies in soft agar (Figure 9d), respectively 
demonstrating enhancement and diminution of anchorage-independent growth which is a 
fundamental criterion for evaluation of proliferative deregulation in malignant 
transformation (XR.Liu et al., 2009; H.Yang et al., 2010). In addition, growth of HLE-AE 
cells is less dependent on exogenous growth factors derived from serum supplement as 
compared with control HLE-MOCK cells, representing auto-secretion of growth factor by 
LAPTM4B-35 overexpressing cells which is another criterion of proliferative deregulation 
and malignant transformation (XL.Liu et al., 2009).  
Moreover, LAPTM4B-35 over-expression alters not only the proliferation-associated 
malignant cellular phenotype, but also the proliferation-regulatory proteins encoded by 
oncogenes and tumor suppressor genes (He et al., 2003; XR. Liu et al., 2009; H. Yang et al., 
2010c). We have found that cell cycle-promoting proteins including cyclin D1, cyclin E and 
p-Rb are up-regulated in LAPTM4B-35 over-expressing HepG2-AE, BEL7402-AE and HLE-
AE cells. At the same time, the transcription factors c-Myc, c-Fos and c-Jun that positively 
regulate expression of cyclins, are also significantly up-regulated. Conversely, the cell cycle-
inhibiting proteins of cyclin-dependent kinase inhibitor (CKI) family, including p16, p21 and 
in particular p27 are markedly down-regulated in these LAPTM4B-35 over-expressing HCC 
cell lines. At the same time, knockdown of endogenous LAPTM4B-35 gives reverse effects 
(Figure 10). These studies serve to identify the molecular basis for deregulated malignant 
proliferation resulting from LAPTM4B-35 over-expression. 
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Fig. 9. Over-expression of LAPTM4B-35 promotes cell proliferation and induces 
deregulation of proliferation. (a) Growth curves determined by MTT assay. Left panel: 
overexpression of LAPTM4B-35 promotes rapid increase in cell viability/proliferation 
compared with the control. Middle panel: knockdown of LAPTM4B-35 inhibits increase in 
cell viability/proliferation as compared with the control. Right panel: restoration of 
LAPTM4B-35 expression in HepG2(M)R cells, in which the RNAi target was mutated, so 
that the siRNA produced from shRNA can not bind to the target mRNA, reverses inhibition 
of cell viability/proliferation resulting from knockdown of LAPTM4B-35. (b) DNA synthesis 
analyzed by BrdU incorporation assay. P < 0.05: HepG2-AE vs. HepG2-mock1, and HepG2-
shRNA vs. HepG2-mock2. (c) Cell cycle analyzed by FACS. P < 0.05: HepG2-AE vs. HepG2-
mock1, and HepG2-shRNA vs. HepG2-Mock2. (d) LAPTM4B-35 promotes colony formation 
in soft agar. Left panel: overexpression of LAPTM4B-35 promoted colony formation (upper); 
knockdown of endogenous LAPTM4B-35 inhibited colony formation (down). Right panel: a 
histogram showing colony numbers larger than 50 µm that were counted 4 weeks after 
seeding. *P < 0.05: HepG2-AE vs. HepG2-mock1; **P < 0.001: HepG2-shRNA vs. HepG2-
mock2. (H. Yang et al., 2010c) 
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Fig. 10. LAPTM4B-35 alters levels of proliferation-regulating proteins analyzed by 
Western blot: (a) Level of p-Rb, c-Myc, cyclinD1 and cyclinE protein was significantly 
increased by over-expression and decreased by knockdown of LAPTM4B-35, respectively. 
Conversely, level of tumor suppressor gene products, p16 and p27, was significantly 
decreased by over-expression and increased by knockdown of LAPTM4B-35, respectively. 
But level of CDK2, CDK4 and p21 was not altered, (b) Restoration of LAPTM4B-35 
expression in HepG2-AE(M)R cells reversed the decrease in c-Myc and cyclinD1 proteins 
resulting from knockdown of endogenous LAPTM4B-35 in HepG2-shRNA cells. (H. Yang 
et al., 2010c). 
3.3 Over-expression of LAPTM4B-35 enhances resistance to induced apoptosis 
Resistance to apoptosis is one of fundamental characteristics of cancer cells. LAPTM4B-35 
over-expressing L02-AE, HepG2-AE and BEL7402-AE cells show marked resistance to drug-
induced apoptosis (Figure 11-13). However, down-regulation of endogenous LAPTM4B-35 
can restore sensitivity of cancer cells to drug-induced apoptosis (L.Li et al., 2010; H.Yang et 
al., 2010c). In addition, up-regulation of LAPTM4B-35 inhibits activation of the apoptosis 
executive caspase 3, up-regulates the anti-apoptotic gene bcl-2, bcl-xL and phosphorylated 
Bad, and also down-regulates the pro-apoptotic gene Bax  and Bid (Figure 12, L.Li et al., 
2011; L. Zhou, 2011). Moreover, PI3K/AKT, a fundamental signaling pathway for cell 
survival is activated by up-regulation of LAPTM4B-35, and is inhibited by down-regulation 
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of endogenous LAPTM4B-35 (L.Li et al., 2010, 2011; H. Yang et al., 2010c). This data serves 
to establish the cellular and molecular basis of resistance to apoptosis promoted by over-
expression of LAPTM4B-35. 
 
 
* P<0.05: Ad-Null vs. Ad-AE 
Fig. 11. Up-regulation of LAPTM4B-35 protects L02-AE cells from adriamycin induced 
apoptosis. (a) LIVE/DEAD Viability/Cytotoxicity Kit assay. Green-stained cells are viable 
cells; cells with red stained nuclear are late apoptotic and dead cells. The LAPTM4B-35 over-
expressing L02-Ad-AE cells show less apoptotic cells as compared with L02-Ad-Null control 
cells. (b) Upper panel: Flow cytometry analysis of apoptosis by Annexin V and PI staining. 
The number of apoptotic L02-Ad-AE cells appeared in early-, late-phase of apoptosis and 
dead phase were all less than L02-Ad-Null cells. Lower panel: The histograms showing the 
cell percentage of dead cells (left) and Annexin V-positive cells in early plus late apoptotic 
phases (right). (c) Apoptosis shown by transmission electron microscopy. Black arrow 
indicates the apoptotic L02-Ad-Null control cell induced by adriamycin; this was not seen in 
L02-Ad-AE cells (L. Li et al., 2011). 
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Fig. 12. Up-regulation of LAPTM4B-35 effects activation or expression of apoptosis-
associated molecules in L02-AE cells. (a) Inhibition of caspase-3 activation in LAPTM4B-
35 over-expressing L02-Ad-AE cells measured by the DEVD cleavage assay. Datum in 
each point represents the mean SD of three independent experiments. ***P < 0.001: L02-
Ad-AE vs. L02-Ad-Null. (b) Cleavage of procaspase-3 and PARP was inhibited by up-
regulation of LAPTM4B-35, demonstrating the inhibition of apoptosis. (c) Up-regulation 
of the anti-apoptotic bcl-2 protein and down-regulation of the pro-apoptotic Bax protein 
in L02-Ad-AE cells analyzed by Western blot. (d) Increase of phosphorylated AKT and 
Bad in L02-Ad-AE cells, suggesting the activation of PI3K/AKT signaling and inhibition 
of apoptosis. (Li et al., 2011). 
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Fig. 13. Up-regulation and down-regulation of LAPTM4B-35 respectively inhibits and 
promotes HepG2 cells apoptosis induced by adriamycin. (a) Adriamycin (15 µg/ml) 
induced apoptosis analyzed by FACS in HepG2-AE, HepG2-shRNA, HepG2-AE (M)R cells 
and corresponding controls. P < 0.05: HepG2-AE cells vs. HepG2-mock1, and HepG2-AE 
(M) R vs. HepG2-shRNA, P < 0.001: HepG2-shRNA vs. HepG2-mock2. (b) Analysis of 
cleaved caspase-3 and PARP by Western blot, demonstrating activation and inhibition of the 
apoptotic pathway respectively by up-regulation and down-regulation of LAPTM4B-35 in 
HepG2 cells.  
3.4 Over-expression of LAPTM4B-35 enhances migration and invasion 
Cell migration and invasion are prerequisites for metastasis. Using LAPTM4B-35 over-
expressing HCC cells, including HLE-AE, HepG2-AE and BEL7402-AE cells, it has been 
demonstrated that the cells over-expressing LAPTM4B-35 display enhanced capacity for 
migration and invasion (XR. Liu et al., 2009; H. Yang et al., 2010c). Conversely down-
regulation of endogenous LAPTM4B-35 by RNAi inhibits migration and invasion of HCC 
cells (Figure 14, H. Yang et al., 2010c). In addition, the matrix metal proteases (MMP2 and 
MMP9) and urine plasminogen activator (uPA) which are key proteases for cancer cell 
invasion, are up-regulated and/or activated by over-expression of LAPTM4B-35 (L. Zhou 
et al., 2010).  
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Fig. 14. Over-expression of LAPTM4B-35 promotes migration and invasion. The left panels: 
(a) Cell migration measured by Boyden chamber assay was promoted and inhibited, 
respectively, by over-expression (upper panel) and knockdown (lower panel) of LAPTM4B-
35 in HepG2 cells. (b) Cell invasion measured by Boyden chamber assay in the presence of 
Matrigel is promoted and inhibited, respectively, by over-expression (upper panel) and 
knockdown (lower panel) of LAPTM4B-35 in HepG2 cells. The right panels are the 
histograms showing number of migratory and invasive cells. *P < 0.05: HepG2-AE vs. 
HepG2-mock1; **P < 0.001 HepG2-shRNA vs. HepG2-mock2. 
3.5 Over-expression of LAPTM4B-35 motivates multi-drug resistance 
Multi-drug resistance is a significant obstacle in cancer chemotherapy. We have 
demonstrated (L Li et al., 2010) that drug efflux and resistance to multiple drugs including 
doxorubicin, paclitaxel and cisplatin, are enhanced in LAPTM4B-35 over-expressing L02-AE 
cells that were originally derived from normal liver (Figure 15a), whereas these phenomena 
are reversed in LAPTM4B-35 down-regulated HeLa-RNAi cells (Figure 15b). In addition, the 
drug retention in HeLa-RNAi cells was significantly more than in HeLa-Mock control cells 
(Figure 15c). These findings imply multi-drug resistance is promoted by over-expression of 
LAPTM4B-35 (L Li et al., 2010). At the same time, LAPTM4B associated multi-drug 
resistance has also been demonstrated in breast cancer (Hu, 2009; Y.Li., 2010) and ovarian 
cancer (Yin, 2011a) by other research groups. Y Li et al. (2010) demonstrated that 
amplification of LAPTM4B and YWHAZ, which was shown by fluorescence in situ  
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Fig. 15. LAPTM4B-35 motivates multi-drug efflux by interaction with P-gp. (a) Upper panel: 
The LAPTM4B-35 over-expressing L02-AE cells show faster efflux of Rhodamine-123 as 
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compaired with L02-Mock control cells. (b) Upper panel: The LAPTM4B-35 knocking 
down HeLa-RNAi cells show slower drug efflux as compaired with HeLa-Mock cells. The 
drug efflux was measured by Laser Scanning Confocal Microscopy (LSCM). Lower Panels 
of (a) and (b): The fluorescence intensity in each cell was monitored and recorded 
separately as each curve. (c) The Rhodamine-123 retention in HeLa-RNAi cells is 
significantly greater than that of HeLa Mock control cells (*P<0.05). The time course of 
Rhodamine-123 retention in LAPTM4B-35 knocking down HeLa-RNAi cells and HeLa-
Mock cells was analyzed by a FACS. (d) Left panel: LAPTM4B-35 is co-localized with P-gp 
(MDR1) mainly at endomembrane organelles in HeLa cells (Bar, 8 mm). Right panel: 
LAPTM4B-35 is co-localized with P-gp  mainly on plasma membrane in PC-3 cells which 
are spreading onto fibronectin substrate (Bar, 20 mm). Co-localization of LAPTM4B-35 
and P-gp was analyzed by Triple-staining immunofluorescence and LSCM. Yellow color 
is the overlapping of green (P-gp) and red (LAPEM4B-35) signals. (e) Interaction of 
LAPTM4B-35 with P-gp analyzed by Co-immunoprecipitation (Co-IP). The antibodies 
used for immuno-precipitation were anti-LAPTM4B-35-N10pAb (left panel) and anti-P-gp 
pAb (right panel). The antibodies used for immuno-blotting (Western blot) were anti-P-gp 
mAb (upper panel) and anti-LAPTM4B-35-N10pAb (lower panel). Interaction of 
LAPTM4B-35 with P-gp is demonstrated by Co-IP analysis of both sets marked with a box 
with red line. (L Li et al., 2010) 
hybridization (FISH), contributes to chemotherapy resistance of breast cancer. Hu et al 
(2009) reported activation of MTDH and LAPTM4B (which are localized at the same gene 
locus) determined by gain of 8q22 via comparative genomic hybridization (CGH) promotes 
chemoresistance and metastasis of breast cancer. These observations are consistent with our 
current results. All these studies indicate that LAPTM4B plays an important role in multi-
drug resistance. Our study on the mechanism indicates that there is a molecular interaction 
and co-localization between LAPTM4B-35 and P-gp (MDR1). P-gp is a classic transporter 
that results in multi-drug resistance by enhancing drug efflux from cancer cells. 
Interestingly, the co-localization presents at the plasma membrane when cancer cells are 
spreading onto extracellular matrix component fibronectin, but at intracellular membrane 
compartments (this may mainly involve endosomes and lysosomes based on the 
distribution pattern) when cancer cells are not spreading onto extracellular matrix 
component (Figure 15d). Since P-gp trafficking between lysosomes and plasma membrane 
plays a critical role in multi-drug resistance (Fu et al., 2004, 2007), our results suggest that 
LAPTM4B-35 may be a significant factor that is involved in the trafficking of LAPTM4B-
35 and P-gp between plasma membrane and intracellular compartments in giving rise to 
multi-drug resistance. The detailed mechanism for this combined trafficking remains to be 
further studied. Additionally, increasing numbers of experiments have recently shown 
that activation of the PI3K/AKT signaling pathway can regulate or enhance multi-drug 
resistance (Abdul-Ghani et al., 2006; Knuefermann et al., 2003; McCubrey et al., 2006; 
Tazzari et al., 2007). Our study indicates that PI3K/AKT signaling pathway is remarkably 
activated by over-expression of LAPTM4B-35 (see section 3.6). Accordingly, PI3K 
inhibitors can inhibit AKT phosphorylation/activation and increase the sensitivity of 
cancer cells over-expressing LAPTM4B-35 to doxorubicin, paclitaxel and cisplatin (L Li et 
al., 2010). Overall, our data provide new insight into the molecular mechanisms of multi-
drug resistance and open a novel avenue for overcoming multi-drug resistance in 
chemotherapy by targeting LAPTM4B-35. 
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3.6 Over-expression of LAPTM4B-35 activates a signaling network associated with 
carcinogenesis 
Over-expression of LAPTM4B-35 in liver and hepatocellular carcinoma cell lines enhances a 
wide range of malignant cellular and molecular phenotypes. The mechanism for the wide 
variety of roles played by over-expression of LAPTM4B-35 is therefore of great interest and 
has provoked scientific attention. We believe the most likely mechanism which may account 
for the findings and phenotypic changes described above is the involvement of LAPTM4B-
35 in a signaling network. Based on the striking similarity of the proline-rich motifs at the N-
terminus of LAPTM4B-35 and at the PI3K p85α regulatory subunit, we first explored the 
effect of LAPTM4b-35 over-expression in HCC cells on activation of the PI3K/AKT 
signaling pathway. We found that LAPTM4b-35 up-regulation constantly activates 
PI3K/AKT signaling which has been shown by increased phosphorylation of AKT and its 
down stream signaling molecules (Figure 16a) in HepG2, BEL7402 HCC cells and HeLa cells 
(L Li et al., 2010; Yang et al., 2010). Furthermore, interaction between the proline-rich motif 
of LAPTM4B-35 N-terminal tail and the PI3K p85α regulatory subunit is demonstrated by 
site-specific mutations, GST-pull down and co-immunoprecipitation (Co-IP) (L Li et al., 
2010; XR Liu et al., 2009; and unpublished data). It is believed that binding of the proline-
rich motif of LAPTM4B-35 to the SH3 domain of PI3K p85α regulatory subunit may release 
the inhibitory effect of p85α regulatory subunit of PI3K on kinase activity of the p110 
catalytic subunit of PI3K. We then found that the phosphorylation of GSK3 and FOXO4, 
both of which are downstream signaling molecules of phosphorylated/activated AKT, is 
promoted by over-expression and attenuated by knockdown of LAPTM4B-35 in HepG2-AE 
cells (Figure 16a). Since GSK3β (Glycogen synthase kinase 3 beta) is inactivated after 
phosphorylation by AKT, as a result the phosphorylation of c-Myc and cyclinD1, which are 
the GSK3β down stream effectors, is thus diminished and increased, respectively, in 
LAPTM4B-35 over-expressing and knocking down cancer cells ȐFigure16bȑ. Sequentially, 
because diminished phophorylation of c-Myc and cyclinD1 can lead to decrease of 
degradation by proteosomes via ubiqutination (Diehl J et al., 1998), as a result, c-Myc and 
cyclinD1 become more stable and thus accumulate in LAPTM4B-35 over-expressing cancer 
cells (Figure 10a and 16c) playing roles in carcinogenesis. On the other hand, FOXO4 is a 
transcription factor of p27. It is known that phosphorylation of FOXO4 may result in 
sequestration in the cytoplasm with resultant loss of its function (Medema et al., 2000). This 
may be the reason that expression of p27 is dramatically diminished by overexpression of 
LAPTM4B-35, but restored by its knockdown via RNAi (Figure 10a). Based on the fact that 
p27 is a member of the cyclin-dependent kinase inhibitor (CKI) family, and that restored 
expression of p27 may inhibit cell proliferation and thus be a favorable prognostic indicator 
for patients with HCC (M.Fiorentino et al., 2000), it is possible that clinical therapy using 
LAPTM4B-35 specific RNA interference may improve the prognosis of HCC patients. In 
addition, the integrin/FAK, RTK/Ras/ERK and Wnt signaling pathways are also activated 
by LAPTM4B-35 over-expression (unpublished data). It has been demonstrated via GST-pull 
down, Co-IP and site-specific mutations that LAPTM4B-35 can interact with several signal 
molecules in cytoplasm and plasma membrane, such as PI3K p85α, FAK, integrins (α5 and 
α6) and RTKs (for example IGF1R), and so on. Taken together, it is evident that LAPTM4B-
35 over-expression activates a signaling network, consisting of at least four signaling 
pathways which are closely associated with hepatocarcinogenesis, metastasis and multi-
drug resistance (Whittaker, 2010). It is proposed that LAPTM4B-35 may act as an organizer 
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or platform of signal molecules which functions at signal network upstream. Further 
investigation of this point will greatly improve our understanding on hepatocarcinogenesis, 
metastasis and recurrence of hepatocellular carcinoma, and will thus provide novel 
strategies for targeted chemotherapy of hepatocellular carcinoma. 
Overall our studies demonstrate there is a relationship of LAPTM4B-35 over-expression 
with up-regulation of proliferation-promoting proteins and down-regulation of 
proliferation-inhibiting proteins in hepatocellular carcinoma cells. This relationship is 
mediated by a signaling network.  
 
Fig. 16. LAPTM4B-35 over-expression activates a signaling network. (a) Over-expression 
and knockdown of LAPTM4B-35, respectively, activates and inhibits PI3K/AKT signaling 
pathway shown by Western blot. AKT activation is generally evaluated by its 
phosphorylations at S 308 and S473 resulting from PI3K activation through its 
phosphorylating product PIP3 and two additional kinases. GSK3 and FOXO4 are both 
down stream effectors of AKT and thus phosphorylated by this activated kinase. (b) 
Phosphorulated c-Myc (p-Myc) is diminished and increased, respectively, by over-
expression and knockdown in HepG2 cells. (c) Degradation of c-Myc is respectively 
diminished by over-expression of LAPTM4B-35 and enhanced by knowdown of LAPTM4B-
35. This experiment was performed via cycloheximide pulse-chase assay, in which stably 
transfected HepG2 cells were treated with 50 µg/ml of cycloheximide to inhibit biosynthesis 
of proteins and harvested at 0, 7, 15 and 30 min., then Western blot with anti-Myc Ab was 
performed to evaluate degradation of c-Myc. The results indicates that up-regulation of 
LAPTM4B-35 enhances stability of c-Myc, and vice versa. 
3.7 LAPTM4B-24 up-regulation induces apoptosis and autophagocytosis, and 
abolishes carcinogenicity of hepatocellular carcinoma cells 
LAPTM4B-24 is an isoform encoded by the LAPTM4B gene. It is a truncated form of 
LAPTM4B-35 by lacking a 91 amino acid sequence at the N-terminus (Shao et al., 2003). We 
have demonstrated that up-regulation of LAPTM4B-24 via transfection with plasmids 
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pcDNA-BE or infection with replication-deficient adenovirus Ad-BE induces apoptosis and 
autophagocytosis of HCC cells, as well as associated cellular and molecular alterations. At 
the same time LAPTM4B-24 up-regulated HCC cells lose its carcinogenicity (unpublished 
data). These studies indicate that LAPTM4B-24 plays an antagonistic role in 
hepatocarcinogenesis. 
In summary, the LAPTM4B-35 plays pivotal roles in keeping cell survival, proliferation, 
migration and invasion, and so on; whereas LAPTM4B-24 plays critical roles in regulating 
programmed cell death, including apoptosis and autophagocytosis. The expressive 
equilibrium of LAPTM4B-35 and LAPTM4B-24 maintains physiological homeostasis of cells. 
Destroy of this equilibrium would lead to diseases. Up-regulation of LAPTM4B-35 leads to 
oncogenesis, while up-regulation of LAPTM4B-24 may plays a role in cancer regression. 
4. LAPTM4B gene and the encoded LAPTM4B-35 protein are predicted to be 
novel markers for diagnosis of hepatocellular carcinoma 
4.1 LAPTM4B-35 is predicted to be a novel marker for diagnosis, pathological grading 
and progression-monitoring of hepatocellular carcinoma 
We have demonstrated via Western blot and immuno-histochemistry that the expression 
levels of LAPTM4B-35 in HCC tissues show a significant positive correlation with 
pathological grade (Figure 17a, and Table 1 and 3), intrahepatic and extrahepatic metastasis 
(figure 17b), TNM stage (Table 1 and 3) and recurrence of HCC (Table 3), and show a 
negative correlation with overall and disease-free postoperative survival (Figure 17c). Upon 
multivariate analysis, elevated expression of LAPTM4B-35 was found to be an independent  
 
Table 3. Expressive level of LAPTM4B-35 in HCC tissues shown by IHC shows significant 
positive correlation to portal vein invasion, TNM staging and recurrence. (H.Yang et al., 2010b). 
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Fig. 17. Correlation of LAPTM4B-35 expression levels in HCC tissues with pathological 
grading, metastasis and postoperative survival time. (a) Level of LAPTM4B-35 protein in 
HCCs shows positive correlation with pathological grade. (b) LAPTM4B-35 expressions in 
HCCs from 65 patients were divided into three groups: ‘‘Low,’’ ‘‘Mediate,’’ and ‘‘High.’’ 
Level of LAPTM4B-35 in HCC shows significant positive correlation with intrahepatic and 
extrahepatic metastasis. *P<0.05. (c) Levels of LAPTM4B-35 in HCCs show significantly 
negative correlation with overall (left) and disease-free (right) postoperative survival of 
cancer patients. (H.Yang et al., 2010a, 2010b).  
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prognostic factor for hepatocellular carcinoma (Yang et al., 2010a, 2010b). In our preliminary 
study we found that about 40% of paired non-cancerous liver tissues in the same HCC 
patients express elevated LAPTM4B mRNA (JJ. Liu et al., 2000). We believe that the non-
cancerous liver tissue of the same one patient with HCC is representing the precancer status 
to variant extents. We therefore suggest that LAPTM4B-35 may be an important and novel 
biomarker for early diagnosis, mornitoring of progression, prediction of metastasis and 
recurrence of HCC, as well as for evaluating prognosis of HCC patients. In addition, we 
have demonstrated that LAPTM4B-35 protein can be released into the blood in the form of 
exosomes. The levels of LAPTM4B-35 in serum of HCC patients are significantly higher than 
those from normal individuals (unpublished data).  
Moreover, a number of other cancers also show the similar association of LAPTM4B-35 with 
clinical and pathological criteria. Cancers which have been evaluated include gallbladder 
cancer (L. Zhou et al., 2007), cholangiocarcinoma (L. Zhou et al., 2008), ovarian cancer (Y 
Yang, 2008; Yin et al., 2011a, 2011b), cervical cancer (Meng et al., 2010), and endometrial 
cancer (Meng et al., 2010). It is likely that LAPTM4B-35 may also find use as a biomarker for 
other solid cancers. 
4.2 LAPTM4B mRNA expressed in circulating tumor cells can be used for predicting 
metastasis 
It is well known that circulating cancer cells have more highly metastatic potential. We 
found that the highly metastatic cancer cell lines derived from one cancer mass express 
higher levels of LAPTM4N-35 than syngenic cancer cell lines of low metastatic potential 
(XR. Liu et al., 2003). We have determined that the LAPTM4B mRNA expressed by a few 
circulating HCC cells can be measured by nested RT-PCR and real time RT-PCR. Therefore, 
testing LAPTM4B mRNA in circulating HCC cells with real time RT- PCR shows promise 
for application of prediction and evaluation of metastasis occurring at an early stage.  
5. LAPTM4B gene and the encoded LAPTM4B-35 protein as a novel 
therapeutic targets 
5.1 Adjusting the expression equilibrium between LAPTM4B-35 and LAPTM4B-24 can 
be a novel strategy for biotherapy of hepatocellular carcinoma  
As described in section 3, the expression equilibrium of LAPTM4B-35 and LAPTM4B-24 
plays a pivotal role in maintaining the physiological status of cells. LAPTM4B-35 promotes 
resistance to apoptosis, deregulation of proliferation, enhancement of migration and 
invasion, and multi-drug resistance. On the other hand, up-regulation of LAPTM4B-24 
increases sensitivity to induction of apoptosis and autophagocytosis. As we have 
demonstrated in our laboratory knockdown of the high expression of the endogenous 
cancer-promoting protein LAPTM4B-35 via RNAi, or elevating the relatively low expression 
of the cancer-inhibiting protein LAPTM4B-24 by transgenic therapy can significantly inhibit 
cancer growth and metastasis and thus may be applicable in cancer biotherapy. Therefore, 
we suggest knockdown of LAPTM4B-35 expression via RNAi or microRNA, and/or up-
regulation of LAPTM4B-24 expression may provide effective strategies for treatment of 
HCC and possibly other cancers.   
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5.2 LAPTM4B-35 is a novel therapeutic target for neoadjuvant chemotherapy 
Neoadjuvant chemotherapy generally targets one or more molecules in signaling pathways. 
As discussed in section 3, over-expression of LAPTM4B-35 promotes hepatocarcinogenesis, 
faster growth of human HCC xenografts and metastasis in mice, and leads to anti-apoptosis, 
deregulation of proliferation, and enhancement of migration and invasion and multi-drug 
resistance. In addition, over-expression of LAPTM4B-35 leads to accumulation of a number 
of cell cycle promoting proteins and survival proteins, and results in down-regulation of a 
number of cell cycle inhibiting proteins and proapoptotic proteins by activating a signaling 
network including at least 4 different signaling pathways. Based on our studies in vitro and 
in vivo, it is clear that LAPTM4B-35 has significant potential as an important novel target for 
cancer treatment. Recently, we have screened out a few small molecules from various 
libraries containing nearly 2000 chemically synthetic compounds. These small molecules are 
able to kill a variety of cancer cells that over-express the LAPTM4B gene and LAPTM4B-35 
protein in vitro, but do not harm the normal fetal liver cells which do not over-express this 
gene. One of these small molecules has been demonstrated to inhibit growth and metastasis 
of human HCC xenografts in nude mice, and results in cellular and molecular alterations 
opposite to those that result from over-expression of LAPTM4B-35 in HCC cells. Some of 
these active small molecules have been demonstrated to be inhibitors of tyrosine kinase 
(unpublished data).  
In summary, this gene and the proteins it encodes harbor great potential for application in 
cancer biotherapy and chemotherapy. 
6. Conclusion and prospective 
LAPTM4B gene and its encoding LAPTM4B-35 protein are over-expressed in 87% of HCC 
and some solid cancers with varying frequencies. The level of LAPTM4B-35 expression in 
HCC tissues shows significant positive correlation with pathological grade, intrahepatic and 
extrahepatic metastasis, and recurrence, and negative correlation with overall and disease-
free postoperative survival of cancer patients, and is thus an independent prognostic factor 
for HCC. Over-expression of LAPTM4B-35 promotes malignant transformation of cell lines 
from normal tissues, including human liver tissue. This result implies that over-expression 
of the LAPTM4B gene and LAPTM4B-35 protein may play pivotal roles in 
hepatocarcinogenesis and progresion. Up-regulated LAPTM4B-35 promotes faster growth 
and metastasis of human HCC xenografts in nude mice, and results in resistance to 
apoptosis, deregulation of proliferation, and enhancement of migration and invasion, as 
well as multi-drug resistance. In addition, overexpression of LAPTM4B-35 leads to 
accumulation of a number of oncoproteins encoded by oncogenes and down-regulation of a 
number of tumor suppressing proteins. In contrast, knockdown of endogenous LAPTM4B-
35 via RNA interfering leads to significant inhibition of growth and metastasis of human 
HCC xenografts in nude mice, and reversion of the cellular and molecular malignant 
phenotypes. The extensive effects caused by LAPTM4B-35 over-expression result from its 
function in activation of a signaling network, including at least 4 signaling pathways that 
are commonly known to be associated with hepatocarcinogenesis (K. Breuhahn, 2010; 
Takigawa, 2008; XH , 2011). Taken together, our studies suggests that LAPTM4B-35 is a key 
molecule which functions upstream of a cancer associated signaling network and plays 
pivotal roles in hepatocarcinogenesis, progression, metastasis, multi-drug resistance and 
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recurrence. Conversely, up-regulation of LAPTM4B-24, an truncated isoform that lacks a 91 
amino acid sequence at the N-terminus of LAPTM4B-35, promotes apoptosis and 
autophagocytosis, and therefore plays an antagonistic role in hepatocarcinogenesis. Overall, 
these data provide new insight into genes and proteins that are potentially important in the 
pathogenesis of liver carcinoma. This harbors great potential for future application as novel 
biomarkers for cancer diagnostics, pathological grading, progression monitoring and 
prognosis, and as novel molecular targets providing new strategies for biotherapy and 
chemotherapy of HCC.  
Up-regulation of expression of the LAPTM4B gene and LAPTM4B-35 protein occur in a 
broad range of human solid cancers and are often associated with poor prognosis, indicating 
there is a common key role for this oncogentic gene and protein in cancer development.  
Although LAPTM4B gene and the encoded LAPTM4B protein have been the subject of more 
than a decade of study, there are still important issues which remain to be resolved. These 
include (1) the underlying mechanism(s) responsible for up-regulation of the LAPTM4B 
gene and LAPTM4B-35 protein in neoplastic transformation; (2) the possibility LAPTM4B 
may be associated with cancer stem cells. Our previous studies indicate that LAPTM4B-35 
over-expressing cancer cells possess characteristics typical of cancer stem cells, including 
apoptosis-resistance, unlimited renewal capacity, metastatic potential and multi-drug 
resistance. In addition, a study by Lee et al., (2010) suggests that LAPTM4B together with 
Gp49a, Sox4, and CD34 genes may be “stemness-related” genes in a primitive hematopoietic 
progenitor cell line EML, and this study demonstrates that these genes are preferentially 
expressed in hematopoietic stem cells and down-regulated in mature hematopoietic cells. 
Study of whether LAPTM4B-35 protein is a marker of cancer stem cells is therefore 
warranted; (3) as it has been shown in our study that LAPTM4B protein localizes at late 
endosomes, lysosomes, mitochondria, and the plasma membrane (unpublished data), it may 
be supposed that trafficking of LAPTM4B protein in cells would be very important for 
execution of its functions, thus it is worthwhile studying when and how LAPTM4B-35 and 
LAPTM4B-24 trafficking functions in normal cells and in cancer cells; (4) the detailed 
molecular mechanism for enhancing function of multi-drug resistance of p-gp (MDR1) by 
LAPTM4B-35 over-expression; (5) the underlying mechanism for metastasis promoted by 
LAPTM4B-35 over-expression; (6) the detailed molecular mechanism for signaling network 
activation by LAPTM4B-35 over-expression in HCC; (7) the sensitivity and specificity of 
LAPTM4B mRNA and LAPTM4B-35 protein as a marker for HCC diagnosis; (8) the 
underlying molecular mechanism for which targeted chemotherapy of small compounds 
depends on LAPTM4B-35 over-expression.  
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